A Phase 1/2 interventional study of Patritumab Deruxtecan in Metastatic Breast Cancer, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.
Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 1/2, and was the 1st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States, Belgium, France and 5 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 23 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Korea, Republic of, Spain and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Canada, Israel and 3 more countries
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 1
First in 2016; this study’s year is marked. 1 started in 2016.
This study's enrollment of 182 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 167 across the 12 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Daiichi Sankyo Co., Ltd., one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
24 studies in Breast Neoplasms by Daiichi Sankyo: 6 open now, 8 under way, 3 of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 1/2, and was the 3rd registered.
Daiichi Sankyo’s Breast Neoplasms studies by the year they started, since 1999.
3 of the studies testing patritumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965766Gustave Roussy, Cancer Campus, Grand ParisPatritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | 2027-04-11 |
| NCT06298084Gustave Roussy, Cancer Campus, Grand ParisDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | 2027-09 |
| NCT06172478Daiichi SankyoA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, from their registry updates:
Among Daiichi Sankyo’s 24 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.
The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.
Key Inclusion Criteria:
Has based on (RECIST) version 1.1
Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the , adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part Only:
Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:
Key Exclusion Criteria:
Has clinically significant corneal disease
Additional Exclusion Criteria for Dose Expansion Part:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive U3-1402 from 1.6 mg/kg to 8.0 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
Drug: Patritumab Deruxtecan
Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
Drug: Patritumab Deruxtecan
Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
Drug: Patritumab Deruxtecan
U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Also known as: U3-1402
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
AEs will be collected systematically from signing of the informed consent form (ICF) through 28 days after last dose
Time frame: Baseline up to 28 days post last dose, up to approximately 9 months
Number of Participants With Best Overall Tumor Response Using Blinded Independent Central Review Based on Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
CR was defined as a disappearance of all target and non-target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target and non-target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target and non-target lesions. Objective response rate is the number of patients with confirmed complete response and confirmed partial response.
Time frame: From screening until disease progresses, up to approximately 9 months
Dose Escalation Part: Area Under the Serum Concentration Time Curve (AUC) of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: AUC of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: AUC of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Escalation Part: Maximum Plasma Concentration (Cmax) of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: Cmax of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: Cmax of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Escalation Part: Time to Maximum Plasma Concentration (Tmax) of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: Tmax of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: Tmax of Anti-HER3-ac-DXd
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Escalation Part: Area Under the Concentration-Time Curve of Total Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: Area Under the Concentration-Time Curve in Total Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Escalation Part: Cmax of Total Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: Cmax of Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: Cmax in Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Escalation Part: Tmax of Total Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
Dose Finding Part: Tmax of Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 4, Day 21 (each cycle is 21 days)
Dose Expansion Part: Tmax in Anti-HER3 Antibody
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
Time frame: Cycle 1, Day 1 to Cycle 3, Day 21 (each cycle is 21 days)
A total of 182 participants who met all inclusion criteria and no exclusion criteria received at least 1 dose of study treatment.
| Milestone | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 15 | 15 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 15 | 15 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease per recist v1.1 | 3 | 3 | 11 | 10 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical progression | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to side effect management of chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to investigator's decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease per recist v1.1 | 0 | 0 | 0 | 0 | 0 | 8 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 31 | 21 | 31 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 31 | 21 | 31 |
| Withdrew: Progressive disease per recist v1.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 24 | 17 | 23 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 1 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Due to investigator's decision considering patient's liver condition | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Due to investigator's decision due to patient's general condition | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Due to investigator's decision because patient was a candidate for surgery | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Patient withdrew consent following 50 treatment cycles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
AEs will be collected systematically from signing of the informed consent form (ICF) through 28 days after last dose
| Participants | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 15 | 15 | 6 | 12 | 12 | 32 | 31 | 21 | 31 |
| Any TEAE Grade ≥3 | 2 | 1 | 11 | 13 | 5 | 7 | 4 | 20 | 24 | 16 | 27 |
| Any TEAE associated with death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 1 |
| Any TEAE associated with study treatment discontinuation | 0 | 0 | 1 | 2 | 2 | 3 | 0 | 4 | 2 | 1 | 3 |
| Any TEAE associated with dose interruption | 1 | 2 | 7 | 12 | 3 | 8 | 6 | 16 | 15 | 10 | 20 |
| Any TEAE associated with dose reduction | 0 | 0 | 2 | 3 | 5 | 2 | 0 | 4 | 9 | 2 | 8 |
CR was defined as a disappearance of all target and non-target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target and non-target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target and non-target lesions. Objective response rate is the number of patients with confirmed complete response and confirmed partial response.
| Participants | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response (PR) | 0 | 1 | 5 | 7 | 3 | 5 | 3 | 11 | 5 | 7 | 5 |
| Stable disease (SD)/Non-CR/Non-PD | 2 | 2 | 7 | 8 | 2 | 5 | 6 | 19 | 17 | 7 | 21 |
| Progressive disease (PD) | 1 | 0 | 3 | 0 | 1 | 2 | 2 | 1 | 7 | 3 | 3 |
| Nonevaluable (NE) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 2 |
| Objective response rate (ORR) | 0 | 1 | 5 | 7 | 3 | 5 | 3 | 11 | 5 | 7 | 5 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng*d/mL | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| AUClast, Cycle 1 | 2470 ± 435 | 4420 ± 1020 | 8690 ± 1070 | 13000 ± 3310 | 16700 ± 4170 |
| AUClast, Cycle 3 | 2400 | 5920 ± 1070 | 13800 ± 3730 | 20500 ± 4070 | 27100 |
| AUCtau, Cycle 1 | 2470 ± 438 | 4420 ± 1020 | 8600 ± 1870 | 13600 ± 3020 | 16700 ± 4170 |
| AUCtau, Cycle 3 | 2420 | 5900 ± 2050 | 13700 ± 3700 | 20300 ± 3200 | 21000 ± 5420 |
| AUCinf, Cycle 1 | 2490 ± 440 | 4470 ± 1060 | 8990 ± 2230 | 14600 ± 3510 | 18300 ± 4920 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng*d/mL | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| AUClast, Cycle 1 | 5540 ± 2020 | 7160 ± 1900 |
| AUClast, Cycle 3 | 18300 ± 2740 | 9360 ± 3670 |
| AUClast, Cycle 4 | — | 23100 ± 8130 |
| AUCtau, Cycle 1 | 6160 ± 1160 | 7630 ± 1920 |
| AUCtau, Cycle 3 | 16600 ± 3760 | 11600 ± 1880 |
| AUCtau, Cycle 4 | — | 22300 ± 8010 |
| AUCinf, Cycle 1 | 6220 ± 1200 | 7800 ± 1990 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng*d/mL | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| AUClast, Cycle 1 | 10500 ± 2850 | 11500 ± 3930 | 11100 ± 4840 | 11400 ± 3820 |
| AUClast, Cycle 3 | 14200 ± 6540 | 20000 ± 14400 | 19300 ± 6830 | 20400 ± 6230 |
| AUCtau, Cycle 1 | 10100 ± 2480 | 11900 ± 3400 | 11700 ± 4430 | 11700 ± 3380 |
| AUCtau, Cycle 3 | 15600 ± 6850 | 22400 ± 12700 | 20300 ± 6830 | 19800 ± 5540 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng/mL | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| Cmax, Cycle 1 | 1040 ± 217 | 1740 ± 421 | 2950 ± 661 | 3660 ± 1080 | 4210 ± 568 |
| Cmax, Cycle 3 | 948 | 1820 ± 284 | 3020 ± 572 | 3870 ± 488 | 3720 ± 973 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng/mL | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| Cmax, Cycle 1 | 1980 ± 300 | 2370 ± 566 |
| Cmax, Cycle 3 | 4230 ± 1120 | 2830 ± 760 |
| Cmax, Cycle 4 | — | 4310 ± 1120 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| ng/mL | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| Cmax, Cycle 1 | 3010 ± 631 | 3520 ± 619 | 3630 ± 744 | 3610 ± 878 |
| Cmax, Cycle 3 | 3020 ± 606 | 4000 ± 672 | 4150 ± 892 | 4090 ± 506 |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| hours | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| Tmax, Cycle 1 | 1.85 (1.80 to 1.88) | 1.68 (1.65 to 2.05) | 1.83 (1.70 to 7.13) | 2.05 (1.68 to 22.83) | 1.98 (1.77 to 6.92) |
| Tmax, Cycle 3 | 2.18 | 1.83 (1.83 to 2.10) | 1.88 (0.73 to 2.08) | 2.03 (0.77 to 4.13) | 4.22 (2.02 to 6.92) |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| hours | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| Tmax, Cycle 1 | 1.86 (1.60 to 4.23) | 2.01 (1.73 to 3.95) |
| Tmax, Cycle 3 | 2.00 (0.82 to 4.00) | 1.93 (0.60 to 3.95) |
| Tmax, Cycle 4 | — | 1.83 (0.73 to 6.95) |
The serum concentrations for anti-HER3-ac-DXd were quantified using the IC-LC/MS assay.
| hours | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| Tmax, Cycle 1 | 1.90 (1.72 to 7.92) | 1.97 (1.60 to 3.98) | 1.98 (1.75 to 7.50) | 1.95 (1.67 to 6.78) |
| Tmax, Cycle 3 | 1.78 (0.63 to 7.10) | 0.93 (0.57 to 6.80) | 2.02 (0.70 to 7.02) | 2.03 (0.77 to 6.97) |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug*d/mL | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| AUClast, Cycle 1 | 114 ± 14.7 | 219 ± 61.0 | 416 ± 128 | 635 ± 171 | 847 ± 248 |
| AUClast, Cycle 3 | 111 | 312 ± 124 | 700 ± 234 | 1080 ± 280 | 1570 |
| AUCtau, Cycle 1 | 114 ± 14.5 | 219 ± 61.0 | 408 ± 115 | 671 ± 169 | 848 ± 248 |
| AUCtau, Cycle 3 | 111 | 311 ± 122 | 682 ± 194 | 1050 ± 249 | 1200 ± 450 |
| AUCinf, Cycle 1 | 115 ± 14.3 | 226 ± 67.3 | 447 ± 153 | 729 ± 186 | 839 ± 203 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug*d/mL | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| AUClast, Cycle 1 | 235 ± 92.7 | 302 ± 87.4 |
| AUClast, Cycle 3 | 933 ± 174 | 486 ± 199 |
| AUClast, Cycle 4 | — | 1110 ± 280 |
| AUCtau, Cycle 1 | 253 ± 58.0 | 341 ± 103 |
| AUCtau, Cycle 3 | 839 ± 220 | 616 ± 138 |
| AUCtau, Cycle 4 | — | 1090 ± 276 |
| AUCinf, Cycle 1 | 260 ± 63.4 | 335 ± 102 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug*d/mL | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| AUClast, Cycle 1 | 525 ± 174 | 570 ± 248 | 543 ± 225 | 528 ± 166 |
| AUClast, Cycle 3 | 831 ± 391 | 1070 ± 656 | 1070 ± 381 | 1000 ± 266 |
| AUCtau, Cycle 1 | 483 ± 140 | 564 ± 178 | 580 ± 200 | 542 ± 158 |
| AUCtau, Cycle 3 | 874 ± 365 | 1200 ± 536 | 1030 ± 366 | 940 ± 243 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug/mL | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| Cmax, Cycle 1 | 39.8 ± 9.55 | 61.6 ± 8.41 | 95.8 ± 13.5 | 136 ± 26.8 | 149 ± 35.3 |
| Cmax, Cycle 3 | 37.6 | 66.8 ± 11.2 | 112 ± 14.1 | 149 ± 24.7 | 165 ± 25.4 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug/mL | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| Cmax, Cycle 1 | 67.9 ± 11.3 | 87.2 ± 33.2 |
| Cmax, Cycle 3 | 139 ± 25.0 | 94.9 ± 10.6 |
| Cmax, Cycle 4 | — | 145 ± 16.6 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| ug/mL | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| Cmax, Cycle 1 | 107 ± 20.3 | 129 ± 21.2 | 126 ± 28.4 | 127 ± 24.4 |
| Cmax, Cycle 3 | 121 ± 27.7 | 152 ± 25.8 | 140 ± 29.7 | 146 ± 21.7 |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| hours | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg |
|---|---|---|---|---|---|
| Tmax, Cycle 1 | 1.85 (1.80 to 2.17) | 1.68 (1.65 to 1.70) | 1.95 (1.70 to 6.87) | 2.00 (1.82 to 7.00) | 2.14 (1.77 to 6.92) |
| Tmax, Cycle 3 | 2.18 | 1.83 (1.83 to 2.10) | 1.88 (0.67 to 6.88) | 2.02 (0.75 to 96.42) | 2.07 (2.02 to 2.13) |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| hours | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg |
|---|---|---|
| Tmax, Cycle 1 | 1.85 (1.60 to 4.07) | 1.80 (1.73 to 6.83) |
| Tmax, Cycle 3 | 3.80 (0.75 to 6.97) | 1.93 (0.65 to 4.07) |
| Tmax, Cycle 4 | — | 3.80 (0.67 to 4.10) |
The serum concentrations for total anti-HER3 antibody LC/MS were quantified using the IC-LC/MS assay.
| hours | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|
| Tmax, Cycle 1 | 1.92 (1.75 to 6.80) | 2.00 (1.60 to 4.13) | 1.87 (1.75 to 6.80) | 1.93 (1.67 to 22.02) |
| Tmax, Cycle 3 | 1.95 (0.68 to 6.97) | 2.10 (0.73 to 7.17) | 1.98 (0.73 to 6.98) | 2.00 (0.65 to 6.90) |
Collected over Adverse events were collected from baseline up to 28 days post last dose, up to 9 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Cohort 1.6 mg/kg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation: Cohort 3.2 mg/kg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | 13/15 (86.7%) | 3/15 (20%) | 15/15 (100%) |
| Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | 11/15 (73.3%) | 9/15 (60%) | 15/15 (100%) |
| Dose Escalation: Cohort 8.0 mg/kg | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Dose Finding: 3.2/4.8/6.4 mg/kg | 10/12 (83.3%) | 4/12 (33.3%) | 12/12 (100%) |
| Dose Finding: 4.2/6.4 mg/kg | 10/12 (83.3%) | 3/12 (25%) | 12/12 (100%) |
| Dose Expansion: HER3 High 4.8 mg/kg | 22/33 (66.7%) | 10/33 (30.3%) | 32/33 (97%) |
| Dose Expansion: HER3-High 6.4 mg/kg | 24/31 (77.4%) | 12/31 (38.7%) | 31/31 (100%) |
| Dose Expansion: HER3-Low 6.4 mg/kg | 18/21 (85.7%) | 7/21 (33.3%) | 21/21 (100%) |
| Dose Expansion: TNBC 6.4 mg/kg | 16/31 (51.6%) | 8/31 (25.8%) | 31/31 (100%) |
| Event | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/3 | 1/3 | 0/15 | 0/15 | 0/6 | 0/12 | 0/12 | 0/33 | 0/31 | 0/21 | 0/31 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/15 | 0/15 | 0/6 | 0/12 | 0/12 | 0/33 | 0/31 | 0/21 | 0/31 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/15 | 1/15 | 1/6 | 0/12 | 0/12 | 0/33 | 0/31 | 0/21 | 0/31 |
| MalaiseGeneral disorders | 0/3 | 0/3 | 0/15 | 0/15 | 1/6 | 0/12 | 0/12 | 0/33 | 0/31 | 0/21 | 0/31 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 1/15 | 2/15 | 1/6 | 1/12 | 0/12 | 0/33 | 3/31 | 0/21 | 1/31 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 0/15 | 0/15 | 0/6 | 1/12 | 2/12 | 1/33 | 0/31 | 1/21 | 2/31 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/15 | 0/15 | 0/6 | 2/12 | 2/12 | 2/33 | 0/31 | 1/21 | 0/31 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/15 | 0/15 | 0/6 | 0/12 | 0/12 | 1/33 | 0/31 | 2/21 | 1/31 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 1/15 | 0/15 | 0/6 | 1/12 | 0/12 | 0/33 | 0/31 | 0/21 | 1/31 |
| CataractEye disorders | 0/3 | 0/3 | 0/15 | 0/15 | 0/6 | 1/12 | 0/12 | 0/33 | 0/31 | 0/21 | 0/31 |
| Event | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 3/3 | 11/15 | 14/15 | 6/6 | 12/12 | 10/12 | 22/33 | 25/31 | 15/21 | 25/31 |
| StomatitisGastrointestinal disorders | 0/3 | 3/3 | 6/15 | 7/15 | 2/6 | 2/12 | 2/12 | 6/33 | 5/31 | 10/21 | 12/31 |
| White blood cell count decreasedInvestigations | 0/3 | 0/3 | 9/15 | 14/15 | 2/6 | 6/12 | 2/12 | 12/33 | 10/31 | 7/21 | 10/31 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 10/15 | 13/15 | 3/6 | 4/12 | 4/12 | 15/33 | 13/31 | 11/21 | 17/31 |
| Neutrophil count decreasedInvestigations | 0/3 | 0/3 | 10/15 | 13/15 | 2/6 | 8/12 | 3/12 | 15/33 | 10/31 | 8/21 | 15/31 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 2/3 | 9/15 | 11/15 | 4/6 | 5/12 | 4/12 | 18/33 | 15/31 | 8/21 | 18/31 |
| VomitingGastrointestinal disorders | 2/3 | 2/3 | 8/15 | 9/15 | 4/6 | 4/12 | 3/12 | 15/33 | 13/31 | 7/21 | 17/31 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/3 | 0/3 | 3/15 | 5/15 | 4/6 | 1/12 | 0/12 | 7/33 | 9/31 | 6/21 | 8/31 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/3 | 10/15 | 7/15 | 3/6 | 3/12 | 1/12 | 11/33 | 11/31 | 6/21 | 10/31 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 8/15 | 8/15 | 3/6 | 4/12 | 1/12 | 13/33 | 19/31 | 5/21 | 10/31 |
Demographic and baseline characteristics were assessed in the Full Analysis Set.
| Age, Continuous(years) | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55.3 ± 10.41 | 62.3 ± 22.74 | 52.1 ± 13.38 | 58.7 ± 11.76 | 50.2 ± 8.45 | 51.8 ± 13.79 | 50.7 ± 11.92 | 56.0 ± 11.95 | 56.9 ± 11.04 | 55.4 ± 12.92 | 58.0 ± 13.73 | 55.6 ± 12.5 |
| Sex: Female, Male(Participants) | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 15 | 15 | 6 | 12 | 12 | 33 | 31 | 21 | 31 | 182 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: Cohort 1.6 mg/kg | Dose Escalation: Cohort 3.2 mg/kg | Dose Escalation/Dose Finding: Cohort 4.8 mg/kg | Dose Escalation/Dose Finding: Cohort 6.4 mg/kg | Dose Escalation: Cohort 8.0 mg/kg | Dose Finding: 3.2/4.8/6.4 mg/kg | Dose Finding: 4.2/6.4 mg/kg | Dose Expansion: HER3 High 4.8 mg/kg | Dose Expansion: HER3-High 6.4 mg/kg | Dose Expansion: HER3-Low 6.4 mg/kg | Dose Expansion: TNBC 6.4 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 6 | 6 | 34 |
| Black of African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 4 |
| Asian | 3 | 3 | 15 | 15 | 6 | 12 | 12 | 19 | 18 | 15 | 24 | 142 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ .
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Nov 2016 to primary completion in Aug 2021, 56 months.
Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in Jul 2022.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 56 months is close to that.
Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Patritumab deruxtecan